OBJECTIVES: The innovative drug Ocrelizumab was approved by FDA, by EMA in 2017. CADTH (Canada) recommends that ocrelizumab be reimbursed for the treatment of relapsing remitting MS (RRMS). Ocrelizumab was registered in 2017 in Ukraine there are 19,200 people have MS, 1,196 patients are diagnosed each year.The aim was to analyze the published HTA reports about the potential cost effectiveness Ocrelizumab for MS.

METHODS: Information analysis of HTA reports on cost-effectiveness models which evaluated Ocrelizumab in versus others treatment In 2017 were published the first HTA reports in some country for reimbursement of innovatibe drugs.

RESULTS: In USA (2017) were published data from a payer perspective. This model showed that Ocrelizumab was associated with a cost savings of $63,822 and longer and QALYs (Δ = 0.556). These data suggest that ocrelizumab is more cost-effective than interferon beta-1a for the treatment of RRMS in USA.

In Canada (2017) CADTH published the cost-utility analysis based on a Markov state-transition model, comparing ocrelizumab with currently available treatments for adult patients with RRMS. Ocrelizumab was more costly yet more effective than comparators and resulted in incremental cost-utility ratios, that ranged from $20,328 per QALY to $39,626 per QALY.

According to data ORATORIO trial was assigned effectiveness for primary progressive multiple sclerosis (PPMS) compared ocrelizumab vs placebo. Confirmed disability progression was 32.9% with ocrelizumab versus 39.3% with placebo. Extended observation is required to determine the long-term safety and efficacy of ocrelizumab.

In Ukraine (2017) HTA submission with adoption of Core Model cost effectiveness of Ocrelizumab for treatment PPMS was sent to Expert Committee of MoH of Ukraine for unmet needs of MS patients.

CONCLUSIONS: The cost-effectiveness models of Ocrelizumab showed potential utility and cost saving for treatment RRMS. It’s need the adaptation of these cost-effectiveness model on Ocrelizumab from budget perspective in Ukraine.